{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DUR-928",
    "query": {
      "intervention": "DUR-928"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T13:50:45.274Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03394781",
      "title": "A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "DUR-928",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-01-22",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2022-10-17",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03394781"
    },
    {
      "nct_id": "NCT03917407",
      "title": "DUR-928 in Patients With Alcoholic Hepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "DUR-928 (Moderate AH)",
          "type": "DRUG"
        },
        {
          "name": "DUR-928 (Severe AH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig James McClain",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "21 Years to 67 Years"
      },
      "enrollment_count": 43,
      "start_date": "2021-06-01",
      "completion_date": "2023-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03917407"
    },
    {
      "nct_id": "NCT04447404",
      "title": "DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "DUR-928",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-09-21",
      "completion_date": "2021-03-04",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04447404"
    },
    {
      "nct_id": "NCT07428538",
      "title": "Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis"
      ],
      "interventions": [
        {
          "name": "Larsucosterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2026-01-29",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07428538"
    },
    {
      "nct_id": "NCT04563026",
      "title": "A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "DUR-928 30 mg",
          "type": "DRUG"
        },
        {
          "name": "DUR-928 90 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo+ Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2021-01-22",
      "completion_date": "2023-09-06",
      "has_results": false,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563026"
    },
    {
      "nct_id": "NCT03837743",
      "title": "Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "DUR-928 Topical Solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Topical Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-02-21",
      "completion_date": "2020-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-09-02",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Miami, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03837743"
    },
    {
      "nct_id": "NCT03432260",
      "title": "A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "DUR-928 30 mg",
          "type": "DRUG"
        },
        {
          "name": "DUR-928 90 mg",
          "type": "DRUG"
        },
        {
          "name": "DUR-928 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-04-18",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-07T13:50:45.274Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432260"
    }
  ]
}